Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid
nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of …
nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of …
[HTML][HTML] The critical contribution of pseudouridine to mRNA COVID-19 vaccines
P Morais, H Adachi, YT Yu - Frontiers in cell and developmental …, 2021 - frontiersin.org
The current COVID-19 pandemic is a massive source of global disruption, having led so far
to two hundred million COVID-19 cases and more than four million deaths worldwide. It was …
to two hundred million COVID-19 cases and more than four million deaths worldwide. It was …
mRNA-based vaccines
F Kowalzik, D Schreiner, C Jensen, D Teschner… - Vaccines, 2021 - mdpi.com
Increases in the world's population and population density promote the spread of emerging
pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional …
pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional …
[HTML][HTML] Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
JT Granados-Riveron, G Aquino-Jarquin - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Currently, there are over 230 different COVID-19 vaccines under development around the
world. At least three decades of scientific development in RNA biology, immunology …
world. At least three decades of scientific development in RNA biology, immunology …
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across
AK Minnaert, H Vanluchene, R Verbeke… - Advanced drug delivery …, 2021 - Elsevier
The recent approval of messenger RNA (mRNA)-based vaccines to combat the SARS-CoV-
2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA …
2 pandemic highlights the potential of both conventional mRNA and self-amplifying mRNA …
A summary of the SARS-CoV-2 vaccines and technologies available or under development
ZA Abdulla, SM Al-Bashir, NS Al-Salih, AA Aldamen… - Pathogens, 2021 - mdpi.com
Since the beginning of 2020, the world has been in a race to develop vaccines that can
control the COVID-19 pandemic. More than 250 projects have been initiated for this …
control the COVID-19 pandemic. More than 250 projects have been initiated for this …
mRNA-based vaccine for COVID-19: they are new but not unknown!
mRNA vaccines take advantage of the mechanism that our cells use to produce proteins.
Our cells produce proteins based on the knowledge contained in our DNA; each gene …
Our cells produce proteins based on the knowledge contained in our DNA; each gene …
Lipid nanoparticles as promising carriers for mRNA vaccines for viral lung infections
M Hajiaghapour Asr, F Dayani, F Saedi Segherloo… - Pharmaceutics, 2023 - mdpi.com
In recent years, there has been an increase in deaths due to infectious diseases, most
notably in the context of viral respiratory pathogens. Consequently, the focus has shifted in …
notably in the context of viral respiratory pathogens. Consequently, the focus has shifted in …
[HTML][HTML] Targeting the undruggable oncogenic KRAS: the dawn of hope
KRAS mutations are the drivers of various cancers, including non–small cell lung cancer,
colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been …
colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been …
Self-amplifying RNA approach for protein replacement therapy
D Papukashvili, N Rcheulishvili, C Liu, Y Ji… - International journal of …, 2022 - mdpi.com
Messenger RNA (mRNA) technology has already been successfully tested preclinically and
there are ongoing clinical trials for protein replacement purposes; however, more effort has …
there are ongoing clinical trials for protein replacement purposes; however, more effort has …